Marvel Biosciences Corp (MRVL) AI Stock Analysis

Marvel Biosciences Corp

(TSXV:MRVL)

Select Model

Rating:46Neutral

Price Target:CAD 0.15▲(26.67% Upside)

Action:reiterated

Date:06/20/26

The score is held down primarily by weak financial performance (no revenue, persistent losses, negative equity, and negative free cash flow indicating ongoing funding/dilution risk). Technical indicators are comparatively neutral-to-slightly constructive, but valuation remains challenged due to negative earnings and no stated dividend yield.

Positive Factors

Improving Net LossThe reduced annual loss indicates some progress in controlling expenses or limiting deterioration. However, the improvement is not yet sufficient to establish a sustainable earnings profile because the company still has no revenue and remains loss-making.

Negative Factors

No Revenue BaseThe absence of revenue is a fundamental commercialization risk for a biotechnology company. Without an established revenue stream, operating costs cannot be self-funded, making long-term sustainability dependent on successful development, partnerships, or external capital.

Marvel Biosciences Corp (MRVL) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 8.84M
Dividend Yield: ―
Average Volume (3M): 87.28K
Price to Earnings (P/E): -4.5
Beta (1Y): -0.38
Revenue Growth: ―
EPS Growth: 25.70%
Country: Canada
Employees: 5
Sector: General
Sector Strength: 55
Industry: Biotechnology

Marvel Biosciences Corp Business Overview & Revenue Model

Company Description

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, a...

Marvel Biosciences Corp Financial Statement Overview

Summary

Income statement shows no revenue and continued operating losses with a sizable net loss. Balance sheet is stressed with negative shareholders’ equity and meaningful debt relative to a small asset base, raising recapitalization/dilution risk. Cash flow remains negative (ongoing cash burn) despite some improvement versus prior periods.

Income Statement

8Very Negative

Balance Sheet

12Very Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Jul 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-385.42K	-547.37K	-302.02K	-887.52K	-1.38M	-613.10K
EBITDA	-1.92M	-1.94M	1.22M	-2.25M	-2.55M	-1.25M
Net Income	-1.39M	-2.21M	-1,650	-2.29M	-2.55M	-3.04M
Balance Sheet
Total Assets	471.73K	326.71K	491.31K	672.39K	913.54K	2.47M
Cash, Cash Equivalents and Short-Term Investments	434.80K	128.85K	345.77K	556.62K	593.21K	2.39M
Total Debt	1.40M	2.31M	1.71M	1.00M	0	0
Total Liabilities	3.21M	4.33M	3.32M	2.39M	718.00K	112.48K
Stockholders Equity	-2.73M	-4.01M	-2.83M	-1.72M	195.54K	2.36M
Cash Flow
Free Cash Flow	-778.84K	-1.15M	-1.18M	-1.33M	-2.19M	-1.37M
Operating Cash Flow	-778.84K	-1.15M	-1.18M	-1.33M	-2.19M	-1.37M
Investing Cash Flow	0	0	0	0	0	381.57K
Financing Cash Flow	824.62K	933.41K	968.64K	1.30M	394.00K	3.16M

Marvel Biosciences Corp Technical Analysis

Technical Analysis SentimentNegative

Last Price0.12

Price Trends

50DMA0.14Negative

100DMA0.15Negative

200DMA0.15Negative

Market Momentum

MACD-0.00Negative

RSI46.08Neutral

STOCH83.33Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MRVL, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.14, and below the 200-day MA of 0.15, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 46.08 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MRVL.

Marvel Biosciences Corp Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TSE:MRVL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TSE:DRUG	47Neutral	CAD 757.87M	-26.55	-12.56%	―	―	-117.77%
TSE:MRVL	46Neutral	CAD 7.56M	-4.49	39.05%	―	―	25.70%
TSE:BETR	41Neutral	CAD 154.50M	-11.36	34.90%	―	―	-266.67%

* General Sector Average

Performance Comparison

TSE:MRVL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:MRVL	Marvel Biosciences Corp	0.12	-0.10	-45.45%
TSE:BETR	Betterlife Pharma Inc.	0.25	0.19	316.67%
TSE:DRUG	Bright Minds Biosciences Inc.	77.00	-0.07	-0.09%
TSE:MYND	Mynd Life Sciences Inc	0.07	0.00	0.00%

Marvel Biosciences Corp Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Marvel Biosciences Extends Private Placement Access to Quebec Investors

Positive

Aug 19, 2026

Marvel Biosciences Corp. is a Calgary-based pre-clinical biotechnology company that redevelops existing, off-patent drugs into new synthetic derivatives aimed at treating neurological and non-neurological diseases. By focusing on targets such as the...

Business Operations and Strategy

Marvel Biosciences’ MB-204 Shows Robust Efficacy in Fragile X Preclinical Study

Positive

Aug 5, 2026

Marvel Biosciences announced positive preclinical results showing its lead drug candidate MB-204 reversed behavioural and cognitive deficits in a Fragile X mouse model in a study run through the FRAXA Drug Validation Initiative. The compound produced...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jun 20, 2026

Marvel Biosciences Corp AI Stock Analysis